Pancreas adenocarcinoma: novel therapeutics.

Krantz, Benjamin A; Yu, Kenneth H; O'Reilly, Eileen M

Krantz, Benjamin A; Yu, Kenneth H; O'Reilly, Eileen M.

Affiliation

Krantz BA; Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Yu KH; Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, USA.
O'Reilly EM; Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, USA. oreillye@mskcc.org.

Chin Clin Oncol ; 6(3): 30, 2017 Jun.

Article in En | MEDLINE | ID: mdl-28705007

Subject(s)

Adenocarcinoma/therapy; Carcinoma, Pancreatic Ductal/therapy; Pancreatic Neoplasms/therapy; Adenocarcinoma/mortality; Carcinoma, Non-Small-Cell Lung/mortality; Carcinoma, Pancreatic Ductal/mortality; DNA Damage; Humans; Immunosuppression Therapy; Immunotherapy; Lung Neoplasms/mortality; Pancreatic Neoplasms/mortality; Tumor Microenvironment

Key words

Pancreas cancer; immunotherapy; therapeutics; tumor microenvironment (TME)

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pancreatic Neoplasms / Adenocarcinoma / Carcinoma, Pancreatic Ductal Limits: Humans Language: En Journal: Chin Clin Oncol Year: 2017 Document type: Article Affiliation country: United States Country of publication: China

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google